Aptar Pharma

	Aptar Pharma, the leader in respiratory drug delivery systems, is dedicated to supporting customers and patients to effectively treat respiratory diseases such as asthma and COPD.

	With 60% of patients failing to comply with their medication regimens, Aptar Pharma strongly believes that patient behavior can be modified using connected, intuitive and user-friendly devices.

	Connected devices provide real time data and objective monitoring with digital solutions. This can boost patient engagement, increase dose adherence and improve patient health outcomes – with patients able to manage treatment more effectively. With improved adherence, healthcare systems could see a reduction in chronic disease hospitalizations, and lower healthcare costs to payers.

	Aptar Pharma offers customers a range of both add-on and fully-integrated c-Devices, and has partnered with several digital health solution providers to develop a portfolio of c-Devices such as MDIs and DPIs. Aptar Pharma’s team assists customers from concept through to regulatory submission, supporting speed-to-market.

Aptar Pharma is proud to be showcasing its c-Device technology at DDL 2017, in Edinburgh from 6th-8th December. The drug delivery systems provider’s exhibition stand features a dedicated Connectivity Hub, supporting the growing field of connected devices.

(Director of Connected Health Business Development at Aptar Pharma)

Articles

From pressurized metered dose inhalers to connected breath-actuated inhaler platforms and dry powder inhalers, Aptar Pharma’s c-Device solutions are developed to meet the unique data stream objectives of its customers

Delivering connected devices for tomorrow’s drug delivery challenges

	 Aptar Pharma’s Connected Devices Portfolio
	Photo: Courtesy of Aptar Pharma 

	Aptar Pharma, a leading global solution provider of innovative drug delivery systems, will once again attend CPhI Worldwide. At booth 42F10, Aptar Pharma will highlight their wide product portfolio and their latest innovations addressing important healthcare technology megatrends.

	A dedicated innovation corner with a special connectivity hub will center on the growing field of connected healthcare solutions. Studies show that 60% of patients fail to comply with their daily medication regimen. Aptar Pharma strongly believes that patient behavior can be changed through connected, intuitive and user-friendly devices - significantly increasing dose adherence and improving patient health outcomes.

	Sai Shankar, Director Business Development – Connected Devices, will present the findings of a recent Aptar Pharma study on its integrated connected pMDI devices, in his briefing 

“Driving Better Patient Outcomes with Connectivity”

 on Tuesday, October 24 at 15h50, at the Innopack Zone G1A13. He will also underline how Aptar Pharma’s connected health devices portfolio is focused on supporting customers and patients to effectively treat diseases such as Asthma and COPD.

	Visit the Aptar Pharma booth and learn more about this and other megatrends affecting drug delivery systems, and see how Aptar Pharma continues to break new ground in innovative healthcare technology solutions.

	Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit 

Aptar Pharma to Showcase Key Innovations and Connected Device Solutions at CPhI 2017

	Aptar Pharma’s Unit-Dose Systems (UDS) are applicable for therapies where a small and very precise amount of active drug formulation is required in a single nasal shot. Some of these therapies delivered intra-nasally require high deposition in targeted areas of the nasal cavity. The nose-to-brain pathway, which may allow therapeutic compounds to enter the CNS requires the targeting of the upper part of the nasal cavity or “the olfactory region”. The UDS Powder is designed to address the nose-to-brain pathway.

	UDS’s primeless feature offers the patient unique ready-to-use convenience that does not exist with traditional multi-dose spray pumps, which need to be primed prior to first use and sometimes re-primed when used infrequently. The device is easy-to-use with one-handed actuation, in any position.

	The UDS Technology Platform is generally used and recommended for the Allergic rhinitis, Pain Management, Central Nervous System, and Vaccines therapies.

	Last year, Aptar Pharma provided the delivery system and regulatory support for Adapt Pharma’s Narcan

 which was the first U.S. FDA-approved nasally administered, needle-free, ready-to use medication that could stop or reverse the effects of an opioid overdose. Aptar Pharma has brought to the partnership its unique experience in nasal drug delivery and regulatory expertise in relation to combination drug-device products successfully supporting Adapt Pharma’s new drug application.

	Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty,personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit 

https://pharma.aptar.com/en-us/dispensing-solutions/uds.html

Aptar Pharma’s Unit-Dose Systems (UDS) are the preferred drug delivery technology spray platforms when dose accuracy and ease of administration are critical in a single nasal for liquid or powder drug delivery. 



Aptar Pharma’s UDS, the gold standard unit-dose systems for disposable use

	Aptar Pharma announced the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG.

	Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl® used in pain management. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuard

 in Europe in several multidose strengths, using Aptar Pharma’s patented electronic lockout system. The approval represents a major milestone for Aptar Pharma, with the e-Lockout device being the first and only fully integrated electronic nasal drug-delivery device to be approved by EMA.

	Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit:

	To download the complete press release:
	

http://news.aptar.com/solutions/aptar-pharmas-electronic-lockout-device-approved-by-ema/

Aptar Pharma’s e-Lockout device is the first and only fully integrated electronic nasal drug delivery device to be approved by a US or European regulatory authority.